Trial | NCT00226915  Report issue

Title

Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma
Randomized Phase III Trial of Conventional Paclitaxel and Carboplatin Versus Dose Dense Weekly Paclitaxel and Carboplatin in Patients With Newly Diagnosed Stage II-IV Mullerian Carcinoma

  • Phase

    Phase 3

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    637
The purpose of the study is to compare progression-free survival of conventional paclitaxel and carboplatin vs weekly paclitaxel and carboplatin in patients with newly diagnosed stage II-IV ovarian epithelial, primary peritoneal, or fallopian tube cancer.
This is a randomized, multicenter study. Patients are stratified according to residual disease 1 cm or less vs more than 1cm, stage II vs III vs IV, and histology (clear cell or mucinous vs. serous or others). Patients are randomized to one of two treatment arms.

Arm I: Patients receive paclitaxel IV over 3 hours and carboplatin IV over 60 minutes on day 1 for 6-9 cycles.

Arm II: Patients receive paclitaxel IV over 1 hour days 1, 8, and 15 and carboplatin IV over 60 minutes on day 1 for 6-9 cycles.

In both arms, cycles repeat 6 cycles every 21 days in the absence of disease progression or unacceptable toxicity. Additional 3 cycles are given if clinical partial or complete response after 6 cycles.

PROJECTED ACCRUAL: A total 600 patients (300 per treatment arm) will be accrued for this study within 3 years. Assuming median progression-free survivals of 16 months and 21 months and a recruitment period of 3 years this can be achieved by recruiting 600 patients designed to have 80 % detect to a difference between the two arms at the two-sided 5% level of statistical significance.
Study Started
Apr 30
2003
Primary Completion
Jun 30
2012
Study Completion
Jun 30
2012
Last Update
Feb 17
2020

Drug Paclitaxel+Carboplatin

Paclitaxel 180mg/m2＋CBDCA AUC6 q21 days x 6-9cycles

Drug Paclitaxel+Carboplatin

Paclitaxel 80mg/m2 weekly ＋CBDCA AUC6 q21 days x 6-9cycles

1 Active Comparator

Drug: Paclitaxel 180mg/m2＋CBDCA AUC6 q21 days x 6-9cycles

2 Experimental

Drug: Paclitaxel 80mg/m2 weekly ＋CBDCA AUC6 q21 days x 6-9cycles

Criteria 

Inclusion Criteria:

Histologically confirmed stage II-IV ovarian epithelial, primary peritoneal, or fallopian tube cancer
No prior chemotherapy
Age: 20 and more
Performance status: ECOG 0-3
1) Absolute neutrophil count at least 1,500/mm3 2) Platelet count at least 100,000/mm3 3) Bilirubin less than 1.5mg/dL 4) SGOT less than 100 IU/l 5) Serum creatinine less than 1.5mg/dL
Written informed consent

Exclusion Criteria:

Patients with ovarian borderline tumor
Patients who have any evidence of the other cancer present within the last 5 years with the exception of carcinoma in situ or intramucosal cancer that is curable with local therapy
Patients with active infection or uncontrolled diabetes
Patients with unstable angina, or those who have had a myocardial infarction within the past 6 months, or patients with serious arrythmia that requires medication
Patients who have a history of hypersensitivity to polyoxyethylated castor oil (Cremophor EL)
No Results Posted